Test developer focuses on supercharging capacity of commercial labs multi-fold
Mammoth Biosciences—the CRISPR-based diagnostics developer whose co-founders include Nobel laureate and genome editing pioneer Jennifer Doudna, PhD—plans to develop, scale-up, and commercialize its molecular diagnostic assay for COVID-19 through partnerships with MilliporeSigma and Hamilton Cos. [Mammoth Biosciences]
Mammoth aims to process approximately 1,500 tests per 8-hour shift with less than an hour of hands-on interaction time—a speed the company said will offer central labs regulated through the Clinical Laboratory Improvement Amendments (CLIA) significant improved speed over traditional PCR tests while maintaining comparable accuracy . . .
